Serratia marcescens bacteremia

clinical features and antimicrobial susceptibilities of the isolates.

W. L. Yu, C. W. Lin, D. Y. Wang

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

From July 1996 to June 1997, 22 adult patients with Serratia marcescens bacteremia were retrospectively studied at China Medical College Hospital. All patients had severe underlying disease, most commonly diabetes mellitus. Eighteen (82%) patients had nosocomial infection. Clinical syndromes included primary bacteremia (68%), pneumonia (14%), urinary tract infection (9%), suppurative thrombophlebitis (5%) and surgical wound infection (5%). Twelve patients had central venous catheters in place at the onset of bacteremia, but only one case met the definition of catheter-related infection. In 14 (64%) patients, portal of entry of S. marcescens infection was unknown. Five (23%) patients had concurrent polymicrobial bacteremia. The overall mortality rate was 50% (11/22). Seven (32%) of the 22 patients died of S. marcescens bacteremia. All isolates were resistant to ampicillin and cephalothin and susceptible to imipenem. Ninety-five percent of strains were susceptible to moxalactam, 68% to amikacin, 55% to ceftazidime, 45% to aztreonam, 32% to ceftriaxone, 27% to gentamicin, 18% to cefoperazone and cefotaxime, and 9% to piperacillin. MICs of various antibiotics demonstrated that ciprofloxacin and imipenem had good activities against S. marcescens, with MIC90 of 0.19 microg/mL and 1.0 microg/mL, respectively. Due to increasing multidrug resistance, choosing appropriate antimicrobial agents such as moxalactam, imipenem, and ciprofloxacin should be highly recommended for the treatment of S. marcescens infections.

Original languageEnglish
Pages (from-to)171-179
Number of pages9
JournalJournal of Microbiology, Immunology and Infection
Volume31
Issue number3
Publication statusPublished - Sep 1998
Externally publishedYes

Fingerprint

Serratia marcescens
Bacteremia
Imipenem
Serratia Infections
Moxalactam
Ciprofloxacin
Aztreonam
Cefoperazone
Cephalothin
Surgical Wound Infection
Catheter-Related Infections
Thrombophlebitis
Piperacillin
Ceftazidime
Amikacin
Cefotaxime
Ceftriaxone
Central Venous Catheters
Multiple Drug Resistance
Ampicillin

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Allergy
  • Immunology and Microbiology(all)

Cite this

Serratia marcescens bacteremia : clinical features and antimicrobial susceptibilities of the isolates. / Yu, W. L.; Lin, C. W.; Wang, D. Y.

In: Journal of Microbiology, Immunology and Infection, Vol. 31, No. 3, 09.1998, p. 171-179.

Research output: Contribution to journalArticle

@article{00aad26a9ee841b5a3996966e20d416b,
title = "Serratia marcescens bacteremia: clinical features and antimicrobial susceptibilities of the isolates.",
abstract = "From July 1996 to June 1997, 22 adult patients with Serratia marcescens bacteremia were retrospectively studied at China Medical College Hospital. All patients had severe underlying disease, most commonly diabetes mellitus. Eighteen (82{\%}) patients had nosocomial infection. Clinical syndromes included primary bacteremia (68{\%}), pneumonia (14{\%}), urinary tract infection (9{\%}), suppurative thrombophlebitis (5{\%}) and surgical wound infection (5{\%}). Twelve patients had central venous catheters in place at the onset of bacteremia, but only one case met the definition of catheter-related infection. In 14 (64{\%}) patients, portal of entry of S. marcescens infection was unknown. Five (23{\%}) patients had concurrent polymicrobial bacteremia. The overall mortality rate was 50{\%} (11/22). Seven (32{\%}) of the 22 patients died of S. marcescens bacteremia. All isolates were resistant to ampicillin and cephalothin and susceptible to imipenem. Ninety-five percent of strains were susceptible to moxalactam, 68{\%} to amikacin, 55{\%} to ceftazidime, 45{\%} to aztreonam, 32{\%} to ceftriaxone, 27{\%} to gentamicin, 18{\%} to cefoperazone and cefotaxime, and 9{\%} to piperacillin. MICs of various antibiotics demonstrated that ciprofloxacin and imipenem had good activities against S. marcescens, with MIC90 of 0.19 microg/mL and 1.0 microg/mL, respectively. Due to increasing multidrug resistance, choosing appropriate antimicrobial agents such as moxalactam, imipenem, and ciprofloxacin should be highly recommended for the treatment of S. marcescens infections.",
author = "Yu, {W. L.} and Lin, {C. W.} and Wang, {D. Y.}",
year = "1998",
month = "9",
language = "English",
volume = "31",
pages = "171--179",
journal = "Journal of Microbiology, Immunology and Infection",
issn = "0253-2662",
publisher = "Elsevier Taiwan LLC",
number = "3",

}

TY - JOUR

T1 - Serratia marcescens bacteremia

T2 - clinical features and antimicrobial susceptibilities of the isolates.

AU - Yu, W. L.

AU - Lin, C. W.

AU - Wang, D. Y.

PY - 1998/9

Y1 - 1998/9

N2 - From July 1996 to June 1997, 22 adult patients with Serratia marcescens bacteremia were retrospectively studied at China Medical College Hospital. All patients had severe underlying disease, most commonly diabetes mellitus. Eighteen (82%) patients had nosocomial infection. Clinical syndromes included primary bacteremia (68%), pneumonia (14%), urinary tract infection (9%), suppurative thrombophlebitis (5%) and surgical wound infection (5%). Twelve patients had central venous catheters in place at the onset of bacteremia, but only one case met the definition of catheter-related infection. In 14 (64%) patients, portal of entry of S. marcescens infection was unknown. Five (23%) patients had concurrent polymicrobial bacteremia. The overall mortality rate was 50% (11/22). Seven (32%) of the 22 patients died of S. marcescens bacteremia. All isolates were resistant to ampicillin and cephalothin and susceptible to imipenem. Ninety-five percent of strains were susceptible to moxalactam, 68% to amikacin, 55% to ceftazidime, 45% to aztreonam, 32% to ceftriaxone, 27% to gentamicin, 18% to cefoperazone and cefotaxime, and 9% to piperacillin. MICs of various antibiotics demonstrated that ciprofloxacin and imipenem had good activities against S. marcescens, with MIC90 of 0.19 microg/mL and 1.0 microg/mL, respectively. Due to increasing multidrug resistance, choosing appropriate antimicrobial agents such as moxalactam, imipenem, and ciprofloxacin should be highly recommended for the treatment of S. marcescens infections.

AB - From July 1996 to June 1997, 22 adult patients with Serratia marcescens bacteremia were retrospectively studied at China Medical College Hospital. All patients had severe underlying disease, most commonly diabetes mellitus. Eighteen (82%) patients had nosocomial infection. Clinical syndromes included primary bacteremia (68%), pneumonia (14%), urinary tract infection (9%), suppurative thrombophlebitis (5%) and surgical wound infection (5%). Twelve patients had central venous catheters in place at the onset of bacteremia, but only one case met the definition of catheter-related infection. In 14 (64%) patients, portal of entry of S. marcescens infection was unknown. Five (23%) patients had concurrent polymicrobial bacteremia. The overall mortality rate was 50% (11/22). Seven (32%) of the 22 patients died of S. marcescens bacteremia. All isolates were resistant to ampicillin and cephalothin and susceptible to imipenem. Ninety-five percent of strains were susceptible to moxalactam, 68% to amikacin, 55% to ceftazidime, 45% to aztreonam, 32% to ceftriaxone, 27% to gentamicin, 18% to cefoperazone and cefotaxime, and 9% to piperacillin. MICs of various antibiotics demonstrated that ciprofloxacin and imipenem had good activities against S. marcescens, with MIC90 of 0.19 microg/mL and 1.0 microg/mL, respectively. Due to increasing multidrug resistance, choosing appropriate antimicrobial agents such as moxalactam, imipenem, and ciprofloxacin should be highly recommended for the treatment of S. marcescens infections.

UR - http://www.scopus.com/inward/record.url?scp=0032151327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032151327&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 171

EP - 179

JO - Journal of Microbiology, Immunology and Infection

JF - Journal of Microbiology, Immunology and Infection

SN - 0253-2662

IS - 3

ER -